A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors.
Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S.
Fukamachi H, et al. Among authors: kim wh, kim sk, kim ys.
J Exp Clin Cancer Res. 2019 Mar 12;38(1):127. doi: 10.1186/s13046-019-1121-3.
J Exp Clin Cancer Res. 2019.
PMID: 30866995
Free PMC article.